PRIMUS : Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis
NCT07647952 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 448
Last updated 2026-06-15
Summary
This study evaluates a Clinical Decision Support System (CDSS), named PRIMUS, designed to support therapeutic decision-making in MS. The CDSS is based on a validated reference database integrating retrospective data from randomized controlled trials and the French national MS cohort (Observatoire Français de la Sclérose en Plaques, OFSEP). This reference database consists of synthetic data derived from these sources.
PRIMUS enables visualization of disease activity at 1 and 2 years under different therapeutic scenarios, based on clinical and MRI characteristics of patients similar to the patient of interest. The CDSS PRIMUS aims to support informed and individualized treatment decisions. Because MRI is a critical marker of disease activity previously acquired MRI scans will be reanalyzed using automated segmentation and validated by a radiologist to standardize lesion assessment across centers. The results will be displayed to the neurologist and, if appropriate shown to the patient using a dedicated viewer, and can be discussed during the consultation.
A cluster-randomized controlled trial, with hospitals as the unit, will be conducted to evaluate the impact of the CDSS on treatment decision-making in patients with relapsing-remitting MS. The primary objective is to assess whether the use of the CDSS influences therapeutic choices during clinical consultations.
The study hypothesis is that use of the CDSS will increase the proportion of high-efficacy treatments initiated or selected, compared with usual care without CDSS support.
In parallel, an optional sub-study using a mixed-methods approach will explore clinicians' and patients' perceptions of, and interactions with, the CDSS.
Conditions
- Relapsing - Remitting Multiple Sclerosis
Interventions
- DEVICE
-
Clinical decision support system
The Clinical Decision Support System (CDSS) PRIMUS is a software (as medical device) designed to support therapeutic decisions in multiple sclerosis (MS) and assist clinicians during consultations in which initiation or modification of MS treatment is considered. The system uses retrospective clinical and MRI data from a reference database to generate visualizations of disease evolution over a 2-year period under different therapeutic scenarios, based on patient-specific characteristics entered by the clinician. PRIMUS does not make treatment recommendations and does not replace clinical judgment. All treatment decisions remain at the discretion of the clinician
Sponsors & Collaborators
-
Nantes University Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-30
- Primary Completion
- 2027-10-31
- Completion
- 2028-07-31
Countries
- France
Study Locations
More Related Trials
-
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
NCT03593590 ·Status: COMPLETED
-
Online Program to Reduce Depression in MS
NCT02740361 ·Status: COMPLETED ·Phase: NA
-
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853 ·Status: COMPLETED
-
Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis
NCT04567264 ·Status: COMPLETED ·Phase: NA
-
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
NCT07225361 ·Status: RECRUITING ·Phase: PHASE4
-
Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
NCT01723631 ·Status: TERMINATED ·Phase: NA
-
DreaMS - Digital Biomarkers for Multiple Sclerosis
NCT04413032 ·Status: COMPLETED ·Phase: NA
-
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
NCT06675955 ·Status: RECRUITING ·Phase: PHASE3
-
A Systems Approach to Understanding Disease Processes in Multiple Sclerosis
NCT05081700 ·Status: COMPLETED
-
OFSEP Very High Definition Cohort
NCT05622643 ·Status: ACTIVE_NOT_RECRUITING
-
Patient Experiences of Multiple Sclerosis (PExMS)
NCT04236544 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Empathy in MS
NCT05332951 ·Status: COMPLETED
-
Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)
NCT01815632 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
NCT06526364 ·Status: RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT06796504 ·Status: RECRUITING ·Phase: NA
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
NCT02861014 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Ocrevus in Relapsing Multiple Sclerosis
NCT04387734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Fingolimod Real World Experience: the French Grand-Est Cohort
NCT02799199 ·Status: COMPLETED
-
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
NCT03606460 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
NCT07280871 ·Status: NOT_YET_RECRUITING
-
The MS-LINK™ Outcomes Study
NCT04735406 ·Status: COMPLETED
-
Out of Pocket Cost Communication in Multiple Sclerosis Patients
NCT04257071 ·Status: COMPLETED ·Phase: NA
-
Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients
NCT03148938 ·Status: COMPLETED ·Phase: NA
-
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
NCT02807285 ·Status: NO_LONGER_AVAILABLE